A review of malaria vaccine clinical projects based on the WHO rainbow table

被引:167
作者
Schwartz, Lauren [1 ,2 ]
Brown, Graham V. [3 ]
Genton, Blaise [4 ,5 ,6 ]
Moorthy, Vasee S. [1 ,7 ]
机构
[1] World Hlth Org, Initiat Vaccine Res, Dept Immunizat Vaccines & Biol, CH-1211 Geneva 27, Switzerland
[2] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
[3] Univ Melbourne, Nossal Inst Global Hlth, Carlton, Vic 3010, Australia
[4] Univ Lausanne Hosp, Infect Dis Serv, Lausanne, Switzerland
[5] Univ Lausanne Hosp, Dept Ambulatory Care & Community Med, Lausanne, Switzerland
[6] Univ Basel, Swiss Trop & Publ Hlth Inst, CH-4002 Basel, Switzerland
[7] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England
关键词
PLASMODIUM-FALCIPARUM MALARIA; CELL-MEDIATED-IMMUNITY; TRANSMISSION-BLOCKING VACCINE; RECOMBINANT PROTEIN VACCINE; PRIME-BOOST IMMUNIZATION; AERUGINOSA EXOPROTEIN-A; LONG SYNTHETIC PEPTIDE; BLOOD-STAGE VACCINE; MONTANIDE ISA 720; IN-VITRO GROWTH;
D O I
10.1186/1475-2875-11-11
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Development and Phase 3 testing of the most advanced malaria vaccine, RTS, S/AS01, indicates that malaria vaccine R&D is moving into a new phase. Field trials of several research malaria vaccines have also confirmed that it is possible to impact the host-parasite relationship through vaccine-induced immune responses to multiple antigenic targets using different platforms. Other approaches have been appropriately tested but turned out to be disappointing after clinical evaluation. As the malaria community considers the potential role of a first-generation malaria vaccine in malaria control efforts, it is an apposite time to carefully document terminated and ongoing malaria vaccine research projects so that lessons learned can be applied to increase the chances of success for second-generation malaria vaccines over the next 10 years. The most comprehensive resource of malaria vaccine projects is a spreadsheet compiled by WHO thanks to the input from funding agencies, sponsors and investigators worldwide. This spreadsheet, available from WHO's website, is known as "the rainbow table". By summarizing the published and some unpublished information available for each project on the rainbow table, the most comprehensive review of malaria vaccine projects to be published in the last several years is provided below.
引用
收藏
页数:22
相关论文
共 158 条
[61]   Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21 [J].
Kashala, O ;
Amador, R ;
Valero, MV ;
Moreno, A ;
Barbosa, A ;
Nickel, B ;
Daubenberger, CA ;
Guzman, F ;
Pluschke, G ;
Patarroyo, ME .
VACCINE, 2002, 20 (17-18) :2263-2277
[62]   A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates [J].
Kubler-Kielb, Joanna ;
Majadly, Fathy ;
Biesova, Zuzana ;
Mocca, Christopher P. ;
Guo, Chunyan ;
Nussenzweig, Ruth ;
Nussenzweig, Victor ;
Mishra, Satish ;
Wu, Yimin ;
Miller, Louis H. ;
Keith, Jerry M. ;
Liu, Teh-Yung ;
Robbins, John B. ;
Schneerson, Rachel .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (03) :1172-1177
[63]   Pre-erythrocytic immunity to Plasmodium falciparum:: the case for an LSA-1 vaccine [J].
Kurtis, JD ;
Hollingdale, MR ;
Luty, AJF ;
Lanar, DE ;
Krzych, U ;
Duffy, PE .
TRENDS IN PARASITOLOGY, 2001, 17 (05) :219-223
[64]   Electroporation of Synthetic DNA Antigens Offers Protection in Nonhuman Primates Challenged with Highly Pathogenic Avian Influenza Virus [J].
Laddy, Dominick J. ;
Yan, Jian ;
Khan, Amir S. ;
Andersen, Hanne ;
Cohn, Amanda ;
Greenhouse, Jack ;
Lewis, Mark ;
Manischewitz, Jody ;
King, Lisa R. ;
Golding, Hana ;
Draghia-Akli, Ruxandra ;
Weiner, David B. .
JOURNAL OF VIROLOGY, 2009, 83 (09) :4624-4630
[65]   Immunity to malaria: more questions than answers [J].
Langhorne, Jean ;
Ndungu, Francis M. ;
Sponaas, Anne-Marit ;
Marsh, Kevin .
NATURE IMMUNOLOGY, 2008, 9 (07) :725-732
[66]   Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers [J].
Lawrence, G ;
Cheng, Q ;
Reed, C ;
Taylor, D ;
Stowers, A ;
Cloonan, N ;
Rzepczyk, C ;
Smillie, A ;
Anderson, K ;
Pombo, D ;
Allworth, A ;
Eisen, D ;
Anders, R ;
Saul, A .
VACCINE, 2000, 18 (18) :1925-1931
[67]   Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers [J].
Le, TP ;
Coonan, KM ;
Hedstrom, RC ;
Charoenvit, Y ;
Sedegah, M ;
Epstein, JE ;
Kumar, S ;
Wang, RB ;
Doolan, DL ;
Maguire, JD ;
Parker, SE ;
Hobart, P ;
Norman, J ;
Hoffman, SL .
VACCINE, 2000, 18 (18) :1893-1901
[68]   PRIMING WITH RECOMBINANT INFLUENZA-VIRUS FOLLOWED BY ADMINISTRATION OF RECOMBINANT VACCINIA VIRUS INDUCES CD8+ T-CELL-MEDIATED PROTECTIVE IMMUNITY AGAINST MALARIA [J].
LI, SQ ;
RODRIGUES, M ;
RODRIGUEZ, D ;
RODRIGUEZ, JR ;
ESTEBAN, M ;
PALESE, P ;
NUSSENZWEIG, RS ;
ZAVALA, F .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (11) :5214-5218
[69]  
López JA, 2001, EUR J IMMUNOL, V31, P1989, DOI 10.1002/1521-4141(200107)31:7<1989::AID-IMMU1989>3.0.CO
[70]  
2-M